Does Molina Healthcare Cover Forteo (Teriparatide)?

How Molina Healthcare Classifies Forteo on Its Formulary

Molina Healthcare places Forteo (teriparatide) on the specialty tier of its prescription drug formulary across Medicaid, Health Insurance Marketplace, and Medicare Advantage product lines. Specialty-tier placement means higher cost-sharing compared to generic or preferred brand drugs, and it triggers additional utilization management controls.

Formulary Tier Placement by Plan Type

Molina operates in more than 20 states, and formulary details vary by state contract and plan year. On Molina Medicaid managed care plans, Forteo typically sits on the highest brand tier or a dedicated specialty tier. Molina Marketplace (ACA exchange) plans generally place it on Tier 4 or Tier 5. Molina Medicare Advantage plans follow CMS formulary guidelines and list teriparatide on the specialty tier with cost-sharing that can reach 25% to 33% coinsurance [1].

Why Specialty Tier Matters for Your Wallet

The wholesale acquisition cost (WAC) of Forteo runs approximately $4,100 for a 28-day supply pen [2]. Because specialty-tier drugs carry coinsurance rather than flat copays on many plans, a member with 25% coinsurance could face over $1,000 per month before any assistance programs. Molina Medicaid plans in states like California, Texas, and Ohio often cap specialty copays at lower amounts due to state Medicaid regulations, sometimes as low as $1 to $4 per prescription [3].

Teriparatide is the only FDA-approved anabolic agent in the parathyroid hormone class with a full generic pathway, though no therapeutically equivalent generic existed as of early 2026. The biosimilar field may shift costs in coming years, but for now, brand Forteo remains the standard dispensed product.

Prior Authorization Requirements for Forteo Under Molina

Molina Healthcare requires prior authorization (PA) for Forteo across all of its plan types. This is standard practice among managed care organizations for high-cost specialty osteoporosis therapies.

What Molina Typically Requires for Approval

PA criteria vary by state, but Molina's clinical policies generally require documentation of the following before approving Forteo:

• A confirmed diagnosis of osteoporosis, defined as a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip on dual-energy X-ray absorptiometry (DXA) [4]
• History of a fragility fracture (vertebral or hip) or very high fracture risk as defined by FRAX score
• Trial and failure of, intolerance to, or contraindication to at least one oral bisphosphonate (alendronate or risedronate) for a minimum of 12 months
• Prescriber must be an endocrinologist, rheumatologist, or other qualified specialist (some state plans accept primary care with documented justification)
• Baseline serum calcium and 25-hydroxyvitamin D levels within normal range

Turnaround Time and Appeals

Molina processes standard PA requests within 72 hours for non-urgent cases and within 24 hours for urgent requests. If denied, members have the right to appeal. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines recommend anabolic therapy as first-line treatment for patients at very high fracture risk, which can serve as supporting evidence in appeals [5].

"For patients with very high fracture risk, including those with recent fractures, fractures on current therapy, or very low T-scores, initial treatment with an anabolic agent followed by an antiresorptive is recommended," according to the AACE/ACE 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis [5].

Step Therapy: Will Molina Make You Try Other Drugs First?

Yes, most Molina plans enforce step therapy before covering Forteo. This means your physician must document that you tried and failed (or cannot tolerate) a first-line bisphosphonate before Molina will authorize teriparatide.

The Typical Step Therapy Sequence

The standard step therapy pathway on Molina plans follows this general order:

1. Generic oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) for at least 12 months
2. Denosumab (Prolia) or zoledronic acid (Reclast) if oral bisphosphonates fail or are contraindicated
3. Forteo (teriparatide) as a third-line option after documented failure of or contraindication to the above

Some Molina state contracts allow physicians to request a step therapy exception when clinical evidence supports starting with anabolic therapy. The Endocrine Society's 2019 guidelines on pharmacological management of osteoporosis in postmenopausal women note that patients with very high fracture risk (recent major osteoporotic fracture within 12 months, T-score <-3.0, or high FRAX probability) may benefit from initial anabolic therapy rather than antiresorptive agents [6].

How to Request a Step Therapy Override

Your prescriber can submit a step therapy exception request directly to Molina's pharmacy benefit manager. The request should include DXA results, fracture history, FRAX score calculation, and a clinical rationale explaining why bisphosphonate therapy is inappropriate. Response time mirrors standard PA timelines.

What Forteo Costs on Different Molina Plan Types

Out-of-pocket costs for Forteo under Molina Healthcare depend heavily on which type of plan you carry. The differences between Medicaid, Marketplace, and Medicare Advantage coverage are significant.

Molina Medicaid Plans

Medicaid members on Molina managed care plans benefit from state-mandated copay caps. In California (Medi-Cal), specialty drug copays are $0 for most members. In Texas, Medicaid copays are capped at $4 for brand-name drugs. Ohio Medicaid limits copays to $3.90 for brand medications [3]. These caps make Forteo far more affordable through Molina Medicaid than through commercial insurance.

Molina Marketplace (ACA) Plans

Marketplace plans carry higher cost-sharing. Depending on the metal tier (Bronze, Silver, Gold), specialty drug coinsurance on Molina Marketplace plans typically ranges from 20% to 40% after the deductible. A Silver plan member with 30% coinsurance facing a $4,100 list price could owe over $1,200 per fill. Cost-sharing reductions (CSR) available to members earning below 250% of the federal poverty level can substantially reduce this amount.

Molina Medicare Advantage Plans

Molina Medicare members in the coverage gap (the "donut hole") pay 25% of the plan's negotiated price for specialty drugs under the Medicare Part D benefit structure. Once catastrophic coverage kicks in (after $8,000 in true out-of-pocket spending in 2025), the member share drops to $0 under the Inflation Reduction Act provisions [7].

Clinical Evidence Behind Forteo Coverage Decisions

Insurance coverage criteria for Forteo are grounded in registration trial data and guideline recommendations. Molina's PA criteria reflect the same clinical evidence that the FDA reviewed during approval.

Key Trial Data

The Fracture Prevention Trial (N=1,637) randomized postmenopausal women with prior vertebral fractures to teriparatide 20 mcg/day or placebo for a median of 19 months. Teriparatide reduced new vertebral fractures by 65% (RR 0.35, 95% CI 0.22 to 0.55) and nonvertebral fragility fractures by 53% (RR 0.47, 95% CI 0.25 to 0.88) [8]. These results established teriparatide as the first anabolic agent with strong fracture reduction data.

The VERO Trial: Forteo vs. Risedronate

The VERO trial (N=1,360) directly compared teriparatide to risedronate in postmenopausal women with severe osteoporosis. At 24 months, new vertebral fractures occurred in 5.4% of the teriparatide group versus 12.0% of the risedronate group (HR 0.44, 95% CI 0.29 to 0.68, P<0.001) [9]. This head-to-head evidence is particularly useful when appealing a Molina denial, because it demonstrates superiority over the bisphosphonate that step therapy requires first.

Sequential Therapy Evidence

The DATA-Switch trial showed that patients who received teriparatide for 2 years followed by denosumab for 2 years achieved greater BMD gains at the spine and hip than any other treatment sequence [10]. This "anabolic first" approach is now recommended by both AACE and the Endocrine Society for very high-risk patients.

How to Reduce Your Out-of-Pocket Cost for Forteo With Molina

Several programs exist to lower Forteo costs even when Molina's specialty copay is high. Not every program works with every plan type, so matching the right assistance to your coverage matters.

Lilly Forteo Savings Card

Eli Lilly offers the Forteo Savings Card for commercially insured patients, which can reduce copays to as low as $4 per month. This card works with Molina Marketplace plans but cannot be used with Medicaid, Medicare, or other government-funded insurance [2]. Maximum annual benefit is typically $10,800, which covers most commercial copay amounts.

Lilly Cares Patient Assistance Program

Uninsured patients or those who cannot afford their cost-sharing may qualify for Lilly Cares, which provides Forteo at no cost. Eligibility is based on income (generally at or below 400% of the federal poverty level) and lack of adequate prescription coverage. This program does not work alongside active Molina Medicaid or Medicare coverage.

Specialty Pharmacy Coordination

Molina routes Forteo through its preferred specialty pharmacy network. Working with Molina's designated specialty pharmacy (rather than a retail pharmacy) is typically required for coverage. The specialty pharmacy can help coordinate PA paperwork, connect you with copay assistance, and set up home delivery with proper cold-chain handling for the teriparatide pen.

State Pharmaceutical Assistance Programs

Several states where Molina operates (New York, New Jersey, Pennsylvania) maintain State Pharmaceutical Assistance Programs (SPAPs) that can wrap around Molina coverage and cover residual copays for qualifying residents. Eligibility varies by state, age, and income.

Forteo Prescribing Considerations That Affect Coverage

Certain clinical factors can influence whether Molina approves or continues Forteo coverage. Understanding these parameters helps you and your prescriber avoid coverage interruptions.

24-Month Lifetime Limit

The FDA approved teriparatide for a maximum of 24 months of use in a patient's lifetime [11]. Molina enforces this limit through quantity management edits at the pharmacy level. After 24 months of cumulative dispensing, Molina will deny further Forteo claims. This limit was originally based on osteosarcoma signals observed in rat studies at exposures 3 to 60 times the human dose, though no causal link has been established in humans after more than 20 years of post-market surveillance [12].

Lab Monitoring Requirements

Molina may require documentation of periodic lab monitoring during Forteo therapy. Serum calcium should be checked within the first few months of treatment, and 25-hydroxyvitamin D levels should be repleted before and during therapy. Some Molina state contracts require a follow-up DXA scan at 12 to 24 months to document treatment response.

Transition Planning After Forteo

Because the 24-month clock is firm, planning the transition to an antiresorptive agent (typically denosumab or zoledronic acid) is part of responsible Forteo prescribing. BMD gains achieved with teriparatide can be lost if antiresorptive therapy is not started promptly after discontinuation [10]. Your prescriber should submit a new PA for the follow-on agent before Forteo ends.

Comparing Forteo Coverage to Other Osteoporosis Drugs on Molina

Forteo is not the only osteoporosis treatment that requires special handling by Molina. Placing it in context with other covered agents helps patients and prescribers plan treatment sequences.

Generic Bisphosphonates (Tier 1)

Alendronate and risedronate are covered on Molina's lowest tier with no prior authorization. A 30-day supply of generic alendronate costs $4 to $15 at most pharmacies. This is why Molina requires bisphosphonate trial before Forteo.

Denosumab/Prolia (Specialty Tier)

Denosumab is also specialty-tier on Molina formularies with PA requirements. It is administered as a 60 mg subcutaneous injection every 6 months, which may have different cost-sharing implications than Forteo's daily injection. The FREEDOM trial (N=7,868) showed denosumab reduced hip fractures by 40% over 3 years versus placebo [13].

Romosozumab/Evenity (Specialty Tier, Restricted)

Romosozumab, a sclerostin inhibitor, is the newest anabolic agent for osteoporosis. Molina covers it on specialty tier with stringent PA criteria, including a cardiovascular risk assessment because of a black box warning for increased MI and stroke risk observed in the ARCH trial [14]. Coverage is limited to 12 monthly doses.

Abaloparatide/Tymlos (Specialty Tier)

Abaloparatide is a PTHrP analog that competes directly with Forteo. The ACTIVE trial (N=2,463) demonstrated an 86% reduction in new vertebral fractures versus placebo at 18 months [15]. Molina formulary placement and PA criteria for abaloparatide are similar to Forteo, and some plans may prefer one over the other based on contract pricing.

How to Check Your Specific Molina Forteo Coverage

Formulary details change annually and vary by state. The most accurate way to verify your Forteo coverage is through direct verification rather than general guidance.

Online Formulary Lookup

Visit Molina Healthcare's website and manage to the "Find a Pharmacy" or "Drug Search" tool for your specific state plan. Enter "teriparatide" or "Forteo" to see tier placement, PA requirements, quantity limits, and preferred alternatives.

Call Molina Pharmacy Services

The phone number on the back of your Molina member ID card connects you to pharmacy benefit services. Ask specifically about Forteo's tier, your expected copay or coinsurance, whether step therapy applies, and which specialty pharmacy is preferred.

Ask Your Prescriber's Office

Most rheumatology and endocrinology offices have staff experienced with Forteo PA submissions. They can run a real-time benefits check through their e-prescribing system to show your exact out-of-pocket cost before the prescription is sent.